NASDAQ:PLRX
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$128.7M, and the diluted share count rose 1.4%.Summary generated from Pliant Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−61.9%
Return on equity−61.5%
Debt / equity0.00
Free cash flow−$128.7M
FCF marginn/a
Share count change+1.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 | 10 | 2 | 0 | 0 |
| Operating income | −98 | −127 | −184 | −228 | −156 |
| Net income | −97 | −123 | −161 | −210 | −149 |
| Free cash flow | −77 | −96 | −117 | −159 | −129 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 4Insider transaction report
Jul 13, 2026 - 8-KDirector or officer change
Jul 13, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026 - 8-KResults of operations and financial condition
May 11, 2026